Benzene Was Identified as a Bone Marrow Poison Before 1900
Medical reports of benzene-induced bone marrow injury began appearing in the late 19th century. To be exact, the first cases of benzene-induced aplastic anemia were reported in 1897. Aplastic anemia is a life-threatening condition in which the bone marrow stops producing blood cells.
Early 20th-century medical literature contains numerous reports of “benzene poisoning,” documenting severe blood abnormalities in exposed workers. These early cases established a central biological fact: benzene targets the bone marrow, the organ responsible for producing red blood cells, white blood cells, and platelets.
The First Benzene-Induced Leukemia Cases
By 1928, physicians began reporting cases of leukemia following benzene exposure. Additional case reports followed in subsequent decades.
In 1948, the American Petroleum Institute (API) issued a Toxicological Review of Benzene acknowledging evidence of malignant change in the bone marrow (leukemia) associated with occupational benzene exposure.
The API review stated:
“As there is a wide variation in individual susceptibility, it is generally considered that the only absolutely safe concentration of benzene is zero.”
In other words, there are no acceptable benzene levels in the blood. That statement is remarkable. Even by 1948, industry toxicologists recognized:
- Individual susceptibility varies.
- There may be no completely safe benzene levels in blood.
- Leukemia was associated with benzene exposure.
In 1965, Browning reviewed 65 cases of benzene-induced leukemia in the medical literature, further strengthening the evidence base.
Regulatory Recognition: Benzene Is a Known Human Carcinogen
The global scientific consensus is clear: benzene is a known human carcinogen that damages the bone marrow.
International Classification
The International Agency for Research on Cancer (IARC) classifies benzene as:
- Group 1 – Carcinogenic to humans
- Carcinogenic to the bone marrow
- A known cause of leukemia and myelodysplastic syndromes (MDS)
- A probable cause of non-Hodgkin lymphoma (NHL)
IARC specifically recognizes that benzene causes malignant changes in the blood-forming tissues, meaning long-term exposure to benzene can lead to blood cancer.
Occupational Exposure Limits Continue to Tighten
The American Conference of Governmental Industrial Hygienists (ACGIH), a scientific organization that evaluates chemical exposure risks, has recently lowered its recommended exposure limit for benzene 25-fold.
ACGIH’s Threshold Limit Values (TLVs):
- Are health-based guidelines
- Reflect current toxicological and epidemiological evidence
- Often become more protective as science evolves
The fact that ACGIH has moved to reduce the recommended exposure limit underscores a critical point:
As the scientific evidence has grown stronger, recommended exposure levels have become more restrictive — not less.
This trend reflects increasing recognition that:
- Even relatively low levels of chronic benzene exposure can pose serious health risks.
- There may be no truly “safe” exposure level for susceptible individuals.
- Bone marrow toxicity can occur at exposure levels previously considered acceptable.
What This Means for Workers
Regulatory limits are not guarantees of safety. They are policy thresholds, often influenced by feasibility and industry considerations, and they have historically been revised downward as new science emerges.
The continued tightening of benzene exposure recommendations is consistent with over a century of evidence showing that benzene is a blood poison capable of causing:
- Aplastic anemia
- Leukemia
- Myelodysplastic syndromes (MDS)
- Multiple myeloma
The Strongest Human Evidence: Cohort Studies
While early evidence came from case reports, the most powerful scientific support comes from long-term cohort studies. One particularly strong piece of evidence is the Pliofilm Rubber Worker Study, which followed approximately 750 Pliofilm rubber workers at three Ohio facilities.
These workers had relatively high benzene exposure.
The findings included:
- Increased risk of leukemia
- Increased risk of multiple myeloma
- Clear dose-response relationship (higher exposure → higher risk)
This study is particularly important because:
- Workers were not exposed to significant confounding carcinogens.
- There was a wide range of benzene exposure levels.
- Researchers were able to demonstrate dose-response.
- Follow-up extended over three decades.
This type of epidemiologic evidence is considered strong support for causation in toxic tort litigation.
How Benzene Damages the Blood and Bone Marrow
Benzene is metabolized in the body into reactive compounds that:
- Damage bone marrow stem cells
- Cause chromosomal abnormalities
- Disrupt normal blood cell production
- Lead to mutations associated with leukemia and MDS
Because the bone marrow continuously produces blood cells, it is particularly vulnerable to toxic injury from benzene.
Over time, chronic exposure can lead to:
- Aplastic anemia
- Myelodysplastic syndrome (MDS)
- Acute Myeloid Leukemia (AML)
- Certain chronic leukemias
- Multiple myeloma
- Certain lymphomas
Occupational Exposure: Who Is at Risk?
Historically, high-risk occupations have included:
- Refinery workers
- Chemical plant workers
- Rubber manufacturing workers
- Printing and pressroom workers
- Mechanics using benzene-containing solvents
- Workers exposed to gasoline and petroleum vapors
Even low-level, repeated exposures over decades can be significant, particularly given the variability in individual susceptibility recognized as early as 1948.
There May Be No “Safe” Level for Some Workers
One of the most important concepts in benzene toxicology is individual susceptibility. As acknowledged in the 1948 API review, there is wide variation in how individuals respond to benzene exposure.
Some workers develop bone marrow disease at exposure levels tolerated by others. This variability has major implications in litigation, including:
- Compliance with regulatory limits does not necessarily mean exposure was safe.
- Regulatory limits are policy decisions, not medical guarantees.
- Scientific consensus recognizes the connection between benzene and blood cancer.
Benzene as a Blood Poison: The Bottom Line
For decades, medical science has recognized that benzene:
- Attacks the bone marrow
- Suppresses blood cell production
- Causes leukemia
- Causes MDS
- Increases the risk of multiple myeloma
It is not a newly discovered hazard.
If You Developed Leukemia After Years of Benzene Exposure
If you or a loved one:
- Worked for many years around benzene-containing products
- Were exposed to gasoline, solvents, printing chemicals, or petroleum products
- Later developed leukemia, MDS, multiple myeloma, or certain lymphomas
You may have legal rights.
At www.BenzeneLawyers.com, we represent individuals who developed blood and bone cancers after long-term occupational benzene exposure. Our cases are built on decades of scientific literature, historical industry knowledge, and modern epidemiology.
Call us at 1-800-BENZENE for a confidential case review.
Citations
- The past suppression of industry knowledge of the toxicity of benzene to humans and potential bias in future benzene research; Peter Infante (2006)
- The past suppression of industry knowledge of the toxicity of benzene to humans and potential bias in future benzene research; Peter Infante (2006)
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; 120 Benzene (2018)
- Benzene and leukemia. An epidemiologic risk assessment; R A Rinsky, et al (1987)
